Andrew Aronsohn

Andrew Aronsohn is an Associate Professor in the Department of Medicine-Gastroenterology at the University of Chicago. His research focuses on hepatitis C virus (HCV) management, liver transplantation outcomes, gut microbiota dysbiosis in liver disease, and public health interventions to eliminate HCV disparities. He contributes to national clinical guidelines (AASLD-IDSA) and has pioneered educational interventions to enhance HCV treatment access in underserved populations.

Key research themes include fecal metabolite profiling for predicting post-transplant infections, microbiota modulation via lactulose, and stigma reduction in HCV care. His work spans 15+ years with over 50 peer-reviewed articles in journals like Cell Host Microbe, Nature Microbiology, and Hepatology. Collaborations include Matthew Odenwald and Te HS on microbiome studies, and Kapuluru Reddy on transplant outcomes.

His articles emphasize translational research bridging basic science (e.g., novel human Pegivirus discovery) and clinical practice (e.g., HCV treatment guidelines). While no formal awards are listed, his work impacts policy and education in viral hepatitis management.